Australia's CSL plans to invest $1.5 billion in US plasma therapy expansion
18/11/2025 12:21
Nov 18 (Reuters) - Australia's CSL CSL.AX on Tuesday said it would invest $1.5 billion in the United States to manufacture plasma-derived therapies, expanding its footprint in the North American country over the next five years. (Reporting by Sneha Kumar in Bengaluru; Editing by Anil D'Silva) ((Sneha.Kumar@thomsonreuters.com))
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX